After the transfer of spleen cells from old CBA/T6T6 mice (greater than 75 weeks) into young syngeneic CBA/Ca recipients there usually follows a selective expansion of the donor T-cell population and the emergence of type B reticulum cell neoplasms (RCN-B), also of donor origin though probably derived not from the T-cells but from lymphoid dendritic accessory cells. As few as one million injected cells led to significant donor T-cell hyperplasia and tumour induction. Injection of cells from young donors did not have such consequences. Similar tumours were induced by transferring syngeneic cells in both C57BL and DBA/2 mice, although in the latter strain there was no requirement for the injected cells to derive from old donors. It appeared that T-cell proliferation was independent of donor accessory cells or RCN-B induction, since injection of enriched T-cells led to few tumours, although the T-cell chimaerism was indistinguishable from that in recipients of unseparated spleen cells. Development of tumours, however, seemed to be dependent upon stimulated T-cells. Recipients of spleen cells from old T-cell-deprived mice did not develop tumours; conversely, tumours, mostly of donor origin, were induced in recipients of young syngeneic cells when an extrinsic stimulus to T-cell proliferation was provided by continued allostimulation. The apparent selectivity of tumorigenesis for donor cells has led to the proposal that cellular relocation, as a result of transfer, may be an important predisposing factor in malignant transformation in circumstances of T-cell stimulation provided by antigenic challenge or by transfer of T-cells from old donors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.